Studies | Designa | Limitationb | Consistencyc | Directnessd | Inmprecisione | Reporting biasf | Strengthg | Gradienth | Counfoundingi | Quality |
---|
Brumbaugh, 2020 | Cohort | 0 | − 1 | 0 | 0 | 0 | 0 | 0 |  + 1 | Low |
Leavy, 2012 | Cohort | 0 | − 1 | 0 | 0 | 0 |  + 2 |  + 1 | 0 | Low |
Martini, 2022 | Case–control | 0 | 0 | 0 | 0 | 0 |  + 1 |  + 1 | 0 | Moderate |
Xie, 2017 | Cohort | 0 | 0 | 0 | 0 | 0 | 0 |  + 1 | 0 | Moderate |
Atladottir, 2016 | Cohort | 0 | 0 | 0 | 0 | 0 |  + 1 |  + 1 | 0 | Moderate |
Persson, 2020 | Cohort | 0 | 0 | 0 | 0 | 0 | 0 |  + 1 |  + 1 | Moderate |
Sugie, 2005 | Case–control | 0 | 0 | 0 | 0 | 0 |  + 1 |  + 1 | 0 | Moderate |
Tawfeeq, 2016 | Case–control | − 1 | 0 | 0 | 0 | 0 |  + 2 |  + 1 | 0 | Low |
Zhang, 2010 | Case–control | 0 | − 1 | 0 | − 1 | 0 |  + 1 |  + 1 | 0 | Low |
Fernandes, 2016 | Cross-sectional | − 1 | 0 |  | − 1 | 0 |  + 1 |  + 1 | 0 | Low |
Al-Ali, 2021 | Case–control | 0 | − 1 | 0 | 0 | 0 | 0 |  + 1 | 0 | Low |
Hisle-Gorman, 2018 | Case–control | 0 | − 1 | 0 | 0 | 0 | 0 | 0 | 0 | Low |
Laxer, 1988 | Case–control | − 1 | − 1 | 0 | 0 | 0 |  + 1 |  + 1 | 0 | Low |
Rolschau, 2020 | Cohort | 0 | − 1 | 0 | 0 | 0 | 0 | 0 | 0 | Low |
Cryan, 1996 | Case–control | − 1 | − 1 | 0 | − 1 | 0 |  + 2 | 0 | 0 | Low |
Lord, 1989 | Case–control | − 1 | 0 | 0 | − 1 | 0 |  + 2 |  + 1 | 0 | Low |
Gillberg, 1983 | Case–control | − 1 | 0 | 0 | − 1 | 0 |  + 2 |  + 1 | 0 | Low |
Mason-Brothers, 1990 | Case–control | − 1 | − 1 | 0 | 0 | 0 | 0 |  + 1 | 0 | Low |
- Quality of evidence and definitions: high quality: further research is very unlikely to change our confidence in the estimate of effect; moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very low quality: any estimate of effect is very uncertain
- aRefers to the basic study design, which we have broadly categorized as randomized trials (high), observational (cohort/case–control) studies (low), and other evidence (very low)
- bRefers to the detailed study methods and execution [serious (− 1) or very serious (− 2) limitation]
- cRefers to the similarity in the estimates of effect across studies [important inconsistency (− 1)]
- dRefers to the extent to which the ‘people’, ‘interventions’, and ‘outcome measures’ are similar to those of interest [some (− 1) or major (− 2) uncertainty about directness]
- eRefers to imprecise or sparse data (− 1)
- fRefers to the high risk of reporting bias (− 1)
- gRefers to the strong (relative risk > 2 or < 0.5; + 1) or very strong (relative risk > 5 or < 0.2; + 2) evidence of association with no plausible confounders
- hRefers to evidence of a dose–response gradient (+ 1)
- IRefers to all plausible confounders that would have reduced the effect (+ 1)